ArticleArchives of medical science : AMS2018
Expression of recombinant allergen, Der f 1, Der f 2 and Der f 4 using baculovirus-insect cell systems.
Article in Archives of medical science : AMS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Establishment and Application of PDCoV Antibody Indirect ELISA Detection Method Based on N Protein.Veterinary sciences · 2025Article
- From skin testing to molecular diagnostics: the precision leap in dust mite allergy diagnosis and clinical translation challenges.Frontiers in allergy · 2025Review
- Heterogenous Induction of Blocking Antibodies against Ragweed Allergen Molecules by Allergen Extract-Based Immunotherapy Vaccines.Vaccines · 2024Article
- Insect Cell-Expressed Major Ragweed Allergen Amb a 1.01 Exhibits Similar Allergenic Properties to Its Natural Counterpart from Common Ragweed Pollen.International journal of molecular sciences · 2024Article
- Brown spider venom toxins: what are the functions of astacins, serine proteases, hyaluronidases, allergens, TCTP, serpins and knottins?The journal of venomous animals and toxins including tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSpecific immunotherapy is critical for alleviating symptoms associated with house dust mite allergy, such as asthma and rhinitis. However, this approach relies on crude extracts, which are often not of sufficient quality or purity and are not standardized. The use of recombinant allergens may enable safer, more effective treatment. MATERIAL AND
methodsUsing our previously constructed plasmids pET28a(+)-Der f 1, pET28a(+)-Der f 2 and pET28b(+)-Der f 4 as templates, the gene fragments coding for the allergens Der f 1, Der f 2 and Der f 4, respectively, of the dust mite
resultsThe recombinant allergens were successfully expressed and purified from a baculovirus expression system introduced into Sf9 cells, which were verified as being of the correct predicted molecular weights by SDS-PAGE. Furthermore, the reactivity to recombinant allergens rDer f 1, rDer f 2, and rDer f 4 was 85.2%, 88.9%, and 44.4%, respectively, in 27 children with asthma and
conclusionsRecombinant allergens from dust mites can be successfully generated using a baculovirus-insect expression system. Furthermore, these recombinant allergens can be used to detect mite sensitivity in sera, highlighting their utility in future work to understand and develop treatment for mite allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.